Total cash and cash equivalents were $349.7 million as of March 31, 2025. Based on current plans and related estimates of anticipated cash inflows from DEXTENZA, the Company believes that its current cash balance is sufficient to support its planned expenses, debt service obligations, and capital expenditure requirements into 2028. This cash projection does not factor in the impact of potential clinical trial activities for AXPAXLI in NPDR and DME.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUL:
- Ocular Therapeutix Inc (OCUL) Q1 Earnings Cheat Sheet
- Ocular Therapeutix initiated with an Outperform at William Blair
- Buy Recommendation for Ocular Therapeutix: Axpaxli’s Potential to Revolutionize nAMD Treatment
- Ocular Therapeutix added to Analyst Current Favorites list at Raymond James
- Ocular Therapeutix initiated with an Outperform at RBC Capital